223 related articles for article (PubMed ID: 21647386)
1. Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest.
Samadi N; Bekele RT; Goping IS; Schang LM; Brindley DN
PLoS One; 2011; 6(5):e20608. PubMed ID: 21647386
[TBL] [Abstract][Full Text] [Related]
2. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis.
Samadi N; Gaetano C; Goping IS; Brindley DN
Oncogene; 2009 Feb; 28(7):1028-39. PubMed ID: 19079345
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells.
Gaetano CG; Samadi N; Tomsig JL; Macdonald TL; Lynch KR; Brindley DN
Mol Carcinog; 2009 Sep; 48(9):801-9. PubMed ID: 19204929
[TBL] [Abstract][Full Text] [Related]
4. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance.
Samadi N; Bekele R; Capatos D; Venkatraman G; Sariahmetoglu M; Brindley DN
Biochimie; 2011 Jan; 93(1):61-70. PubMed ID: 20709140
[TBL] [Abstract][Full Text] [Related]
5. Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells.
Zhang R; Wang J; Ma S; Huang Z; Zhang G
BMC Cell Biol; 2011 Mar; 12():11. PubMed ID: 21406114
[TBL] [Abstract][Full Text] [Related]
6. Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis.
Li S; Wang B; Xu Y; Zhang J
Mol Cancer; 2011 Feb; 10():18. PubMed ID: 21314984
[TBL] [Abstract][Full Text] [Related]
7. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.
Bacus SS; Gudkov AV; Lowe M; Lyass L; Yung Y; Komarov AP; Keyomarsi K; Yarden Y; Seger R
Oncogene; 2001 Jan; 20(2):147-55. PubMed ID: 11313944
[TBL] [Abstract][Full Text] [Related]
8. Role of the autotaxin-lysophosphatidate axis in the development of resistance to cancer therapy.
Tang X; Benesch MGK; Brindley DN
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Aug; 1865(8):158716. PubMed ID: 32305571
[TBL] [Abstract][Full Text] [Related]
9. Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy.
Brindley DN; Lin FT; Tigyi GJ
Biochim Biophys Acta; 2013 Jan; 1831(1):74-85. PubMed ID: 22954454
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Taxol-induced cell death are concentration dependent.
Torres K; Horwitz SB
Cancer Res; 1998 Aug; 58(16):3620-6. PubMed ID: 9721870
[TBL] [Abstract][Full Text] [Related]
12. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.
Lu J; Tan M; Huang WC; Li P; Guo H; Tseng LM; Su XH; Yang WT; Treekitkarnmongkol W; Andreeff M; Symmans F; Yu D
Clin Cancer Res; 2009 Feb; 15(4):1326-34. PubMed ID: 19228734
[TBL] [Abstract][Full Text] [Related]
13. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.
Zhang H; Xu X; Gajewiak J; Tsukahara R; Fujiwara Y; Liu J; Fells JI; Perygin D; Parrill AL; Tigyi G; Prestwich GD
Cancer Res; 2009 Jul; 69(13):5441-9. PubMed ID: 19509223
[TBL] [Abstract][Full Text] [Related]
14. Autotaxin and lipid signaling pathways as anticancer targets.
Braddock DT
Curr Opin Investig Drugs; 2010 Jun; 11(6):629-37. PubMed ID: 20496257
[TBL] [Abstract][Full Text] [Related]
15. The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer.
Quan M; Cui JJ; Feng X; Huang Q
Tumour Biol; 2017 Mar; 39(3):1010428317694544. PubMed ID: 28347252
[TBL] [Abstract][Full Text] [Related]
16. The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer.
Teo K; Brunton VG
Biochem J; 2014 Oct; 463(1):157-65. PubMed ID: 25195735
[TBL] [Abstract][Full Text] [Related]
17. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway.
Woods CM; Zhu J; McQueney PA; Bollag D; Lazarides E
Mol Med; 1995 Jul; 1(5):506-26. PubMed ID: 8529117
[TBL] [Abstract][Full Text] [Related]
18. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
[TBL] [Abstract][Full Text] [Related]
19. Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment.
Venkatraman G; Benesch MG; Tang X; Dewald J; McMullen TP; Brindley DN
FASEB J; 2015 Mar; 29(3):772-85. PubMed ID: 25398768
[TBL] [Abstract][Full Text] [Related]
20. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest.
Ling X; Bernacki RJ; Brattain MG; Li F
J Biol Chem; 2004 Apr; 279(15):15196-203. PubMed ID: 14722122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]